The book is available for free / open access here:
academic.oup.com/book/61632

thanks Jaime!

Read the full report, but recs here: 4/4

But the authors make a strong case that supply is more stable than many policy folks have assumed.

That’s good news for efforts to move faster on access to a growing pipeline of promising vaccines.

The bad news is that there is a thin margin for error if supply is interrupted. 3/4

The report is careful, even conservative, in its reassurances. The market for quillay vaccine products, derived from Chilean soapbark trees, is currently a monopoly and at best an oligopoly in the near term. 2/4

If you're a journalist, maybe don't write a story on this one in case it's on the list of programs that have survived because someone didn't know about it to kill it.

You don't need a degree in IP to understand what is happening: the Special 301 investigation is part of a continued assault on the right to health and on the established legal instruments available to countries to realize it.

Trade policy should not be weaponized to restrict access to meds. 4/4

Also want to flag the fantastic work of a group of leading IP academics who also submitted analysis.

@hyoyoonkang.bsky.social @grahamdutfield.bsky.social Vitor Ido, @akapczynski.bsky.social, Luke McDonagh, @cmorten.bsky.social

Their submission here: comments.ustr.gov/sfc/servlet.... 3/4

The submission discusses the substantive merits of the 301 investigation. Briefly:
-Claims on patent pendency are based on PhRMA statistics and do not reflect reality
-Overzealous customs enforcement will lead to generic seizures
-The US continues to get confused abt "and" vs "or" in TRIPS 39.3 2/4